Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.54 |
| ▸ | F10 | P00742 | 9/20 | 0.53 |
| ▸ | MAOB | P27338 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | CALML3 | P27482 | 1/20 | 0.50 |
| ▸ | SDHA | P31040 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5209849 | 0.91 | MAOA (0.64) | MAOAF10MAOBLMNAPTGS1 | |
| SCHEMBL5727202 | 0.90 | MAOA (0.53) | MAOAF10MAOBLMNAPTGS1 | |
| SCHEMBL7710552 | 0.90 | MAOA (0.53) | MAOAF10MAOBLMNAPTGS1 | |
| SCHEMBL7702033 | 0.89 | F10 (0.53) | MAOAF10MAOBLMNAPTGS1 | |
| SCHEMBL6040232 | 0.89 | MAOA (0.54) | MAOAF10MAOBLMNAPTGS1 | |
| SCHEMBL6161441 | 0.89 | MAOA (0.53) | MAOAF10MAOBLMNAPTGS1 | |
| SCHEMBL5725953 | 0.87 | MAOA (0.59) | MAOAF10MAOBLMNAPTGS1 | |
| SCHEMBL6310601 | 0.87 | F10 (0.49) | MAOAF10MAOBLMNAPTGS1 | |
| SCHEMBL5727199 | 0.86 | MAOA (0.53) | MAOAF10MAOBLMNAPTGS1 | |
| SCHEMBL6210774 | 0.86 | CALML3 (0.56) | MAOAF10MAOBCALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1668005-B1 | ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES | PHARMACIA & UPJOHN CO LLC (US) | 2007-02-14 | — | — | EP | disclosed |
| EP-1328509-B1 | METHODS OF PRODUCING OXAZOLIDINONE COMPOUNDS | PHARMACIA & UPJOHN CO LLC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-6998420-B2 | Oxazolidinone compounds | PHARMACIA & UPJOHN COMPANY (US) | 2006-02-14 | — | — | US | disclosed |
| US-6833453-B2 | As an example, manufacturing a 5-(tert-butylcarbamoyl)-amino-methyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protected derivative of glycidylamine or a 3-amino-1-halopropanol | PHARMACIA & UPJOHN COMPANY | 2004-12-21 | — | — | US | disclosed |
| EP-1328509-A1 | METHODS OF PRODUCING OXAZOLIDINONE COMPOUNDS | Pharmacia & Upjohn Company (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20020086900-A1 | Methods of producing oxazolidinone compounds | PERRAULT WILLIAM R (US) | 2002-07-04 | — | — | US | disclosed |
| WO-2002032857-A1 | METHODS OF PRODUCING OXAZOLIDINONE COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086900-A1 | Methods of producing oxazolidinone compounds | TET3, TET1, AZI2 | MAOA 3150/4885F10 3027/4885MAOB 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.